Cerus (CERS) Gains from Investment Securities (2013 - 2022)

Cerus (CERS) reported Gains from Investment Securities of $1.9 million for Q4 2022, up 475.07% on a YoY basis from $337000.0 in Q4 2021, and up 21433.33% sequentially from $9000.0 in Q3 2022.

Cerus (CERS) Gains from Investment Securities (2013 - 2022) Analysis & Trends

Cerus (CERS) has 5 years of Gains from Investment Securities data on file, last reported at $1.9 million in Q4 2022.

  • For the quarter ending Q4 2022, Gains from Investment Securities rose 475.07% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2022 stood at $2.2 million (up 1575.0% YoY), and the FY2022 full-year result was $2.2 million, up 1575.0% from the prior year.
  • Gains from Investment Securities grew to $1.9 million in Q4 2022, from $9000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.9 million in Q4 2022 to a low of -$220000.0 in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn
8 Smith & Nephew 26.99 Bn 26.41 Bn -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn
10 Cerus 600.87 Mn 520.44 Mn 27.89 Mn

Historic Data

Download Data
DateValue
Dec 31, 2022 1.94 Mn
Dec 31, 2022 1.94 Mn
Sep 30, 2022 9,000.00
Sep 30, 2022 9,000.00
Jun 30, 2022 -45,000.00
Jun 30, 2022 -45,000.00
Mar 31, 2022 281,000.00
Mar 31, 2022 281,000.00
Dec 31, 2021 337,000.00
Dec 31, 2021 337,000.00
Sep 30, 2021 -83,000.00
Sep 30, 2021 -83,000.00
Jun 30, 2021 -182,000.00
Jun 30, 2021 -182,000.00
Mar 31, 2021 -220,000.00
Mar 31, 2021 -220,000.00
Dec 31, 2015 1.13 Mn
Dec 31, 2015 1.13 Mn
Sep 30, 2015 -1.11 Mn
Sep 30, 2015 -1.11 Mn